A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis.
Launched by PFIZER · Nov 6, 2008
Trial Information
Current as of May 12, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients must be at least 18 years of age at screening
- • Males and female patients with clinical diagnosis of ulcerative colitis ≥3 months prior to entry into the study.
- • Male and female patients with active currently moderate to severe ulcerative colitis defined by Mayo score of ≥6
- • Patients with endoscopic sub-score of ≥2 on the Mayo score determined within 7 days of baseline.
- Exclusion Criteria:
- • Diagnosis of Crohn's disease or diagnosis of indeterminate colitis
- • Treatment naive subjects who have not had previous exposure to treatment for ulcerative colitis
- • Patients that are currently receiving immunosuppressants, anti-TNFα therapy or interferon
About Pfizer
Pfizer Inc. is a global leader in biopharmaceutical innovation, dedicated to discovering, developing, and delivering advanced therapies that enhance patient outcomes across a wide range of medical conditions. With a rich history of scientific research and a commitment to quality, Pfizer focuses on areas such as oncology, immunology, cardiology, and rare diseases. The company leverages cutting-edge technology and collaborates with healthcare professionals, regulatory bodies, and academic institutions to conduct rigorous clinical trials that ensure the safety and efficacy of its products. Pfizer's mission is to bring breakthroughs that change patients' lives, exemplifying its commitment to health and wellness worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Porto Alegre, Rs, Brazil
Antwerpen, , Belgium
Leuven, , Belgium
Aarhus C, , Denmark
Vaxjo, , Sweden
Amsterdam, Nh, Netherlands
Glasgow, , United Kingdom
Barcelona, , Spain
Bologna, , Italy
Roma, , Italy
Wroclaw, , Poland
Gent, , Belgium
São Paulo, Sp, Brazil
Marseille Cedex 20, , France
L'hospitalet De Llobregat, Barcelona, Spain
Sao Paulo, Sp, Brazil
Gyor, , Hungary
Johannesburg, Gauteng, South Africa
Lille Cedex, , France
Tel Aviv, , Israel
Olomouc, , Czech Republic
Usti Nad Labem, , Czech Republic
Aalborg, , Denmark
Umea, , Sweden
Szeged, , Hungary
Bekescsaba, , Hungary
Mosonmagyarovar, , Hungary
Budapest, , Hungary
Debrecen, , Hungary
Nantes Cedex 1, , France
Manchester, , United Kingdom
Szentes, , Hungary
Kaposvar, , Hungary
Lodz, , Poland
Bydgoszcz, , Poland
Bristol, , United Kingdom
Durban, Kwa Zulu Natal, South Africa
Haifa, , Israel
Hradec Kralove, , Czech Republic
Gyula, , Hungary
Szekszard, , Hungary
Bratislava, , Slovakia
Nitra, , Slovakia
Miskolc, , Hungary
Bordeaux Cedex, , France
Independencia, Santiago Rm, Chile
Vina Del Mar, , Chile
Usti N. Labem, , Czech Republic
Petah Tikva, , Israel
Delegacion Benito Juarez, Mexico Df, Mexico
Tlalpan, Mexico Df, Mexico
Overport, Durban, South Africa
Claremont, Western Cape, South Africa
Durbanville, Western Cape, South Africa
Majadahonda, Madrid, Spain
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials